CD274 and neoplasm: In vitro studies also suggest that unlike other Fc-null PD-L1 blocking antibodies such as durvalumab, sugemalimab retains the binding to FcγR I and therefore could efficiently induce antibody-dependent cellular phagocytosis through crosslinking of PD-L1 positive tumor cells with macrophages that are prevalently present in the tumor microenvironment [19].